Seeking Alpha HealthcareOriginal article
Kiniksa projects $980M-$995M 2026 revenue guidance while advancing KPL-387 into Phase III PASTORALE
Phase 3KPL-387Positive
AI Analysis
Summary
Kiniksa projects 2026 revenue guidance of $980M-$995M and advances its KPL-387 candidate into the Phase III PASTORALE trial.
Clinical Trial Data
Phase
Phase 3
Financial Highlights
Guidance
$980M-$995M for 2026
Outcome Details
KPL-387 advancing into Phase III PASTORALE trial
Importance:6/10
Sentiment:
0.60
Phase 3 advancementrevenue guidanceclinical development
Related Companies
Read the original article
Published by Seeking Alpha Healthcare on July 28, 2026 2:25 PM